INT197766

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.60
Pain Relevance 0.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

enzyme regulator activity (Sln)
Anatomy Link Frequency
SLN 1
Sln (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 9 93.80 High High
Bioavailability 14 88.08 High High
transdermal 18 75.00 Quite High
imagery 2 63.80 Quite High
anesthesia 3 59.84 Quite High
Pain 2 5.00 Very Low Very Low Very Low
Neuritis 1 5.00 Very Low Very Low Very Low
cINOD 1 5.00 Very Low Very Low Very Low
carrageenan induced 1 5.00 Very Low Very Low Very Low
rheumatoid arthritis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Melanoma 45 99.80 Very High Very High Very High
Metastasis 29 99.44 Very High Very High Very High
Diabetes Mellitus 12 97.24 Very High Very High Very High
Cutaneous Melanoma 7 96.04 Very High Very High Very High
Pressure And Volume Under Development 7 95.56 Very High Very High Very High
INFLAMMATION 9 93.80 High High
Disease 1 62.80 Quite High
Cancer 10 59.16 Quite High
Nevus 5 5.00 Very Low Very Low Very Low
Toxicity 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The amount of drug bound to the SLN was found to increase with the increase in the stearic acid concentration and this may be due to the higher intactness of the lipid.
SLN Binding (bound) of
1) Confidence 0.32 Published 2008 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2792476 Disease Relevance 0 Pain Relevance 0
Both the SLN and NLC dispersions and gels enriched with SLN and NLC possessed a sustained drug release over period of 24 h but the sustained effect was more pronounced with the SLN and NLC gel


Background

SLN Binding (enriched) of
2) Confidence 0.32 Published 2009 Journal Lipids Health Dis Section Abstract Doc Link PMC2651881 Disease Relevance 0.19 Pain Relevance 0.15
The reduction of the initial glucose levels versus time after intragastric insulin-loaded SLN, insulin solution and subcutaneous administration of insulin is depicted in Figure 2.
SLN Binding (intragastric) of
3) Confidence 0.24 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.10 Pain Relevance 0.03
SLN characterization
SLN Binding (characterization) of
4) Confidence 0.24 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.07 Pain Relevance 0
Thus, prevailing evidence supports the evaluation of SLN for melanoma metastases as the standard of care to identify subset of patients with metastases in cutaneous melanoma.
SLN Binding (evaluation) of in SLN associated with melanoma, cutaneous melanoma and metastasis
5) Confidence 0.07 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1592125 Disease Relevance 1.25 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox